The pathomorphologist’s role in the era of personalised therapy regarding the case of colorectal tumours by Kołos, Małgorzata et al.
386
Review article
NOWOTWORY Journal of Oncology
2016, volume 66, number 5, 386–395 
DOI: 10.5603/NJO.2016.0069 
© Polskie Towarzystwo Onkologiczne
ISSN 0029–540X
www.nowotwory.edu.pl
1Department of Pathomorphology 
Central Clinical Hospital of the Ministry of the Interior and Administration, Warszawa, Poland 
2 The Faculty of Medicine and Health Sciences
The Jan Kochanowski University, Kielce, Poland 
The pathomorphologist’s role in the era of personalised therapy 
regarding the case of colorectal tumours
Małgorzata Kołos1, Anna Nasierowska-Guttmejer1, 2, Anna Wasążnik-Jędras1
Colorectal cancer is one of the most common epithelial tumours amongst humans. Effective treatment requires  
a multidisciplinary approach and in some cases target therapy. In order to introduce treatment, both the clinical stage 
and pathomorphological diagnosis have to be taken into account. An analysis of the microscopic appearance as well 
as immunohistochemical and molecular tests are the basis of proper diagnosis. Biomarkers for diagnosis of colorectal 
cancer can be divided into two groups. The first one constitutes diagnostic and prognostic markers which are com-
monly used by pathologists. They are useful in the recognition of morphological and clinical features of tumours. 
The second group of biomarkers is used additionally and has predictive value. In an era of personalised therapy, the 
pathomrothologist’s role is to assess the prognostic and predictive biomarkers, in order to identify patients who will 
benefit from molecular targeted therapy. In the case of colorectal cancer mutations of genes: KRAS, NRAS and BRAF are 
clinically significant. A lack of the aforementioned mutations correlates with a better response to anti-EGRF therapy.
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Introduction 
Colorectal cancer (13% in males [M] and 10% in fema- 
les [F]), breast cancer (23% in F), lung cancer (20% in M and 
9% in F) and prostate cancer (15% in M) in 2012 belonged 
to the most frequently diagnosed cancers and accounted 
for 48% of the total causes of diseases in men and 42% in 
women (65 310 cases altogether) [1]. The above cancers are 
more and more frequently treated with personalised thera-
py, based on a detailed morphological report containing the 
evaluation of prognostic and predictive factors with immu-
nochemistry and/or molecular reports. Modern oncological 
treatment requires, on the one hand, the collaboration of 
interdisciplinary teams consisting of diagnostic specialists, 
radiologists, pathologists, molecular biologists and clini-
cians (direct contact between the pathomorphologist and 
oncologist is of particular importance). On the other hand, 
however, the evaluation of the real costs of the pathologi-
cal and morphological evaluation is necessary. Within the 
context of the wider debate on financing the treatment of 
patients at least one medical service such as chemotherapy, 
radiotherapy, surgical intervention or palliative care should 
be taken into account. According to the analyses of Ko-
zierkiewicz at al. [2], the estimated expenses of the National 
Health Fund for the treatment of about 15  000 cases of 
breast cancer per year, in 2004–2010, amounted to 2,893 
billion PLN. This amount, however, does not take into con-
sideration the diagnostics, which, in the case of oncological 
therapy (especially a molecularly targeted one) makes up 
a significant element on the costs list. 
Colorectal cancer is an example of a cancer in which the 
patient prognosis and the treatment costs depend on the 
clinical stage at the moment of diagnosis. The choice of the 
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treatment method is made on the basis of a pathological 
report with an evaluation of predictive factors. The correct 
result of microscopic examination depends significantly on 
the method of protecting the specimen collected during 
a surgery, its fixation method (the type of fixer and time of 
fixation) and the quality of the macroscopic evaluation [3]. 
Of special importance is the number of lymph nodes found 
(in the cancer of the colon) and the evaluation of the total 
mesorectal excision with the verification of the radial margin 
in the colorectal cancer. In the case of finding fewer than 
12 lymph nodes in the colon surgery specimen, the patient 
undergoes adjuvant therapy, similar to that undertaken with 
palliative patients. The above parameters are the basis for 
the evaluation of the quality of the work of the surgeon 
and pathomorphologist [4]. The microscopic characteristics 
which are obligatorily evaluated are: histologic type and the 
tumour grade, the tumour stage in pTNM AJCC/UICC score, 
the features of the vessels and nerves involvement, surgical 
margins (distal, proximal and radial in segments of the large 
intestine without the serous membrane) and the degree of 
the tumour regression after the neoadjuvant therapy. The 
above parameters are listed in the recommendations of the 
Polish Society of Pathologists [4, 5]. 
In an era of targeted therapy, a modern pathology depart-
ment requires special organisation. The requirements posed 
by oncologists for pathologists and molecular biologists have 
increased. The moments of key significance for the quality of 
the correct results of the immunohistochemistry (IHC) and 
molecular tests are the pre-analytical stage (securing, preser-
vation and technical processing of the tissue material), identi-
fication of the neoplastic tissue by the pathomorphologist for 
molecular tests and the validation and standardisation of the 
IHC and molecular methods. The work pattern in a modern 
pathology department according to the recommendations of 
the European and British pathological societies is illustrated 
in Figure 1 [6]. A pathomorphologist collaborating with an 
oncologist should have at their disposal a laboratory with 
automatic equipment which allow for obtaining repetitive 
results in the evaluation of biomarkers.
Biomarkers in the diagnostics of  
colorectal cancer 
The biomarkers which are useful in the diagnostics of 
cancers can be divided into two groups. The first one com-
prises mainly immunohistochemistry biomarkers used by 
pathologists for routine diagnostics. In some selected cases, 
molecular methods are applied. They both have diagnostic 
and prognostic significance and are useful for the inter-
pretation of morphological and clinical characteristics of 
neoplasms as they define the direction of cellular differ-
entiation. Once applied in routine diagnostics processes, 
they allow for the determination of the histological type of 
primary tumour or establish the histological genesis of the 
metastasis. It must be stressed that they are subject to both 
external and internal control measures.
The latter group comprises the biomarkers with the 
predictive value, the usefulness of which has been evidence-
based. They are recommended by clinicians and are used 
for the selection of treatment methods and monitoring the 
course of the disease. They can be divided into biomarkers 
whose expression is determined with immunohistochemis-
try methods and and/or the markers whose disorders in ger-
minal or somatic cells are detected with molecular methods. 
They should undergo external quality control (EQC), which 
should be carried out among others by European organisa-
tions such as the European Society of Pathology (ESP) [6, 7].
Diagnostic and prognostic biomarkers — group I
The biomarkers within the first group are useful for 
a pathomorphologist to confirm the diagnosis of the his-
tological type of the tumour. Sometimes the microscopic 
variant of a cancer or sarcoma has a prognostic value which 
has clinical significance for the course of the disease. The 
practical significance of biomarkers was applied for the di-
agnostics of colorectal cancers and its microscopic subtypes, 
neuroendocrine tumours, lymphomas and stromal tumours 
(GIST), and the most frequent mesenchymal cancers of the 
gastrointestinal tract.
The biomarkers of the first groups (both diagnostic and 
prognostic) are divided into two groups: those useful for 
differential diagnostics (IA) and for the identification of car-
cinogenesis pathways (IB). 
The biomarkers useful for differential diagnostics of 
colorectal cancers (IA)
The immunohistochemistry-based differential diagnos-
tics of colorectal cancers requires the application of antibod-
ies’ panel for immunohistochemistry tests. The guidelines 
for this type of diagnosis are discussed below.
Adenocarcinoma
The most frequent histological type of colorectal cancer 
is the adenocarcinoma. The biomarkers which confirm its 
epithelial differentiation comprise keratins which are char-
acterised by a positive reaction to staining in the cytoplasm 
of the cancer cells for CK20 and predominantly negative 
cytoplasmic expression for CK7. The immunohistochemical 
profile of the types: CK7–/CK20+ is present in 95% of colo-
rectal cancers (and also in the majority of Merkel cell cancers 
and in almost one third of gastric adenocarcinomas) [8]. The 
marker which is useful in the case of the identification of 
a metastasis of a colorectal cancer to another organ or in the 
case of poorly differentiated primary colorectal cancer is the 
transcription factor CDX-2; the marker of proliferation and 
differentiation from the intestinal epithelium. It represents a 
positive nuclear reaction to staining in the cells of the normal 
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mucosa of the large intestine and nuclear or nuclear and 
cytoplasmic reaction in the cells of the large intestine [9]. 
Moreover, ectopic CDX2 expression is found in 85% of 
acute myeloid leukaemias [10] and in the cases of Barrett’s 
oesophagus in which the bile acids induce intestinal dif-
ferentiation (metaplasia) of the cells of the gastric glandular 
epithelium [11, 12].
Recently there have been studies carried out concerning 
the usefulness of the AMACR antibody in the oncological 
supervision of patients with ulcerative colitis (UC). This an-
tibody, used routinely in patients with prostate cancer does 
not manifest expression in normal large intestine mucosa, 
whilst it is present in the low degree dysplasia foci (96%), 
high degree dysplasia foci (80%) and in neoplastic infiltra-
tion (71%) [13].
Apart from the above colorectal adenocarcinoma, in the 
discussed location, there are also other types of cancers. This 
group comprises the cancers with microsatellite instability 
(MSI) connected with hereditary nonpolyposis colorectal 
cancer (HNPCC — Lynch syndrome) or sporadic cancer. The 
antibodies panel which can confirm the cancers with MSI 
and differentiate them from the classical adenocarcinoma 
(CIN) comprises: the MLH1, MSH2, MSH6, PMS2 and TP53 
antibody [14]. The differentiation of the classical adenocar-
cinoma, connected with poorer prognosis, from cancers 
with MSI, in particular of mucinous or medullary type, whose 
prognosis is better, has a great clinical significance.
Neuroendocrine tumours
Gastrointestinal neuroendocrine tumours require the 
confirmation of the diagnosis with the following immuno-
histochemistry tests: obligatorily Synaptophysin and Chro-
mogranin A and, conditionally, CD56 or any other specific 
endocrine markers. In any case, it is necessary to evaluate 
the proliferative activity of KI-67 (MIB1); a value below 20% 
confirms the diagnosis of neuroendocrine cancer (NEC). The 
above biomarkers have a diagnostic and prognostic value 
and proliferative index — has also predictive value.
Stromal tumour of the alimentary tract (GIST)
GIST is another example of the alimentary tract tumour 
which requires special pathological diagnostics with the use 
of biomarkers. In comparison with other segments of the 
digestive tract, it occurs quite rarely in the large intestine (5% 
of cases in the anus and 1% of cases in the colon). It must 
be stressed that GIST in distal location has a significantly 
poorer prognosis than in a proximal one [15]. The progres-
sion risk of large intestine GIST in the cases with more than 
5 division figures into 50 large visual fields and a diameter 
ranging from 5 to 10 cm is 85% in comparison with 55% in 
the case of stomach GIST [16]. In a microscopic evaluation, 
GIST manifests a heterogenous microscopic appearance 
with an epithelioid, spindle or polymorphic cell. That is why 
the IHC evaluation of the biomarkers expression, and, in 
some cases also the molecular tests of the KIT and PDGFRA 
Figure 1. Work algorithm in a modern pathomorphology department (as modified by the authors on the basis of publication I. Cree [6])
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genes mutation confirm GIST diagnosis and differentiate it 
with other large colon neoplasms. The tests which confirm 
the diagnosis of this lesions are: immunohistochemical ex-
pression of CD117 (KIT) [17], membranous type of reaction 
(discohesive, hypercellular and sarcomatous types of GIST), 
perinuclear or pancytoplasmatic stain (spindle cell type of 
GIST) as well as Anoctamine 1 (DOG1) found in 100% of 
cases [15]. It must also be observed that the lack of CD117 
expression may be indicative of PDGFRA mutation. About 
80% of GIST CD117 negative tumours manifest a PDGFRA 
gene mutation, whilst the remaining cases (10–15%) are wild 
type tumours (WT). They manifest neither KIT not PDGFRA 
mutations. Less specific GIST biomarkers are CD34 (60–70%), 
H-Caldesmon (85%), SMA (30–40%), S100 (5%) and Calponi-
na (9). In some selected cases, it is recommended to carry out 
a differential diagnosis with melanoma (HMB45, Melan A or 
S100 antibodies), seminoma (PLAP, CD30), dysgerminoma 
(D2-40) or an aggressive fibromatosis type lesion (nuclear 
expression of b-catenin) [16].
Lymphomas and mesenchymal cell tumours  
with a definite differentiation direction
Lymphomas and mesenchymal cell tumours with 
a definite direction of differentiation whose prevalence in 
the large colon is quite rare, require the conformation with 
ICH biomarkers, and sometimes with molecular tests. Their 
diagnostics should be performed in oncological centres. 
Some specific tumour types with a useful panel of immu-
nohistochemistry tests are presented above (Tab. I).
The biomarkers of colorectal cancer  
carcinogenesis pathway (IB) 
The second group of diagnostic and prognostic bio-
markers comprises the biomarkers of the neoplastic trans-
formation pathway of the colon epithelium. Adenocarcino-
mas develop of the basis of three carcinogenic pathways. 
There are cancers with chromosomal instability (CIN), satel-
lite instability (MIN) and cancers with CpG islands instabi- 
lity [18, 19]. The above division is presented on Figure 2. Such 
lesions may occur as a result of genetic disorders (mutations 
and changes of the cellular DNA) or epigenetic disorders 
(gene modifications with DNA methylation) [20]. The panel 
immunohistochemistry markers: TP53, MLH1, MSH2, MSH6, 
PMS2 allow for a preliminary determination of the pathway 
of neoplastic transformation, differentiating cancers with 
MSS from cancers with MSI-H and MSI-L [18, 19]. The evalu-
ation of germinal mutations of APC genes and MMR genes 
has a prognostic value.
APC gene mutations
In the cases of a classical CIN carcinogenesis pathway, the 
APC gene mutation and activation of the Wnt pathway occurs 
and is responsible for about 90% of cases of cancers of the 
large colon [21]. A small number of large colon cancers (less 
than 1%) is hereditary and occurs as a result of the germinal 
mutation of the APC gene (familial adenomatous polyposis 
— FAP) or MUTYH gene mutation (MUTYH-related polypo- 
sis) [22, 23]. The germinal mutation of the APC gene, in compari-
son with the somatic mutation of this gene, has a prognostic 
value, as it identifies the patients burdened with a risk of the 
development of colorectal cancer at a young age. The mean 
age of the person in whom this cancer develops is 40 years. 
The risk of development at the age of 21 varies between 1% 
and 6%, whilst at the age of 50 years, it is more than 95% [24].
In sporadic cancers, the somatic mutations of the APC 
gene occur. Also the mutations of the function loss concern-
ing the TP53 suppressor gene (known as “the guardian of 
the genome”), are found in such cases. Overexpression of 
the TP53 protein can be diagnosed with the immunohis-
tochemistry method. The nuclear accumulation occurs at 
an early stage of the neoplastic transformation to intraepi-
thelial neoplasia. It must be stressed that the confirma-
tion of the TP53 gene mutation is done by molecular tests. 
A microscopic image of the tubular adenoma together with 
the immunohistochemistry evaluation of the TP53 protein 
is presented in Figures 3a and 3b. 
Table I. The panel presenting immunohistochemical differential diagnostics confirming the histological genesis of a tumour
Cancer type IHC panel for differential diagnosis
Large colon adenocarcinoma CK20, CDX-2, CK7
Large colon neuroendocrine tumours Obligatory: Synaptophysin, Chromogranin A, Ki-67
Conditional: CD56
GIST of the large colon Obligatory: CD117
Conditional: DOG1, CD34, H-Caldesmon, SMA, S100, Calponina, HMB45, Melan A, S100, 
PLAP, CD30, D2-40, b-catenin
Lymphomas LCA, CD3, CD20, BCL2
Muscle type neoplasms SMA, Desmina, H-Caldesmon
Nerve type neoplasms S100, GFAP
Myofibroblastic neoplasms ALK1, Desmina, SMA
Vascular type neoplasms CD31, D240
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MMR genes mutations
The pathway connected with microsatellite instability 
(MIN) is responsible for the development of Lynch syndrome 
(polyposis-related hereditary large colon cancers, making up 
3% of large colon cancers) and for sporadic cancers (12% of 
large colon cancers) [25, 26]. In these cases, there is a muta-
tion of mutator genes coding the proteins taking part in the 
mismatched nitrogen bases (MMR — mismatch repair genes). 
The evaluation of the loss of immunohistochemistry 
expression of the MLH1, MSH2, MSH6, PMS2 proteins (lack 
of colour nuclear reaction) allows to diagnose the mutator 
subtype of cancer. The diagnostic and prognostic value 
of IHC and the molecular test is justified in these cases. 
The germinal mutations of MMR genes can conform Lynch 
syndrome (autosomally dominating with mutations of at 
least one of the MMR genes) or Muir-Torre syndrome (MTS) 
(autosomally dominating with mutations of the MSH2 gene, 
more rarely of MLH1), which, together with a family history 
may identify the families burdened with a risk of multiple 
synchronous or metachronous cancers with MSI.
In sporadic cancers, there are somatic mutations of MMR 
genes or epigenetic disorders, such as hypermethylation. It 
is significant that the first stage in the diagnostics of large 
colon cancers with MSI consists in macro and microscopic 
features, such as right-side location, histological type and 
heterogenicity of the architecture, the presence of mucus 
and signet ring cells, type of inflammatory infiltrates, the 
presence of necrosis and the type of tumour growth mar-
gins. The next stage is the performance of IHC and molecular 
tests.
CpG Islands hypermethylation (CIMP)
The third carcinogenesis pathway consists in silenc-
ing suppressor genes responsible for the regulation of the 
transcriptions in the mechanism of the CpG islands hyper-
methylation. The precursor changes of large colon cancers 
occurring through the CIMP are serrated changes, accom-
panied by BRAF gene mutations (V600), the methylations 
of the promotors of various genes and the methylations of 
the MLH1 promotor. Large colon cancers with CIMP are more 
frequent in women, in right-side location and have MSI-H 
microscopic features [14]. The immunohistochemistry evalu-
ation of MLH1 allows the detection of the loss of protein 
expression in a tumour. The prognostic significance of this 
carcinogenic pathway is still under discussion.
Predictive biomarkers — II group
The basis for the implementation of targeted therapy in 
cancer patients is the determination of the factor connected 
with the target of the drug effect and identification of patients 
who would benefit from the treatment. In practise, the quali-
fication of the patients for treatment requires the obligatory 
evaluation of predictive factors studied by a pathologist as 
well as a molecular biologist. The immunohistochemistry 
evaluation of the expression of the proteins produced by the 
selected genes or molecular changes of these genes allow 
one to predict an individual response to treatment.
The patients with advanced stage of disease, with dis-
tant metastases (stage IV) are recommended to receive 
targeted therapy with EGFR inhibitors: cetuximab and pani-
tumumab, monoclonal antibodies directed at extracellular 
Figure 2. Carcinogenesis pathways of colorectal cancer
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domain and small particles of tyrosine kinases inhibitors. 
EGFR, belonging to the family of tyrosine kinase inhibi-
tors, is a defined target in the therapy of colon cancer. Its 
overexpression, found in numerous solid tumours, is also 
a cause of a poor prognosis in these patients. Before the 
implementation of an anti-EGFR therapy, it is necessary to 
evaluate the predictive factors connected with intracellular 
signalling pathways (IIA group biomarkers). The practical 
significance of the biomarkers connected with the carcino-
genesis pathways of large colon cancers, such as WNT (IIB 
group), and epigenetic disorders with MSI (IIC group), is still 
at the clinical trial stage.
Biomarkers of intracellular signalling pathways (IIA)
Anti-EGFR therapy in the treatment of colorectal cancer 
is directed at somatic molecular disorders of the genes lead-
ing to the activation of the intracellular signalling pathways: 
RAS – RAF – miogen-activated protein kinase (MAPK), phos-
phatidylinositol 3-kinase (PIK3K) – AKT and phospholipa- 
se C (EGFR/RAS/RAF/MEK/MAPK, PTEN/PIK3K). In normal 
situation, this pathway is controlled by EGFR. In the case of 
EGFR overexpression and the activation of the signalling 
pathway the neoplastic cells are activated and thus the can-
cer cells proliferate, apoptosis is inhibited and their survival 
time is prolonged. This leads to an increased cancer invasion, 
increased angiogenesis, growth of distant metastases and 
cancer progression. 
The activation of the intracellular signalling pathways is 
the outcome of dimerization and phosphorylation resulting 
from the connection of EGF (epidermal growth factor) or any 
other ligand with EGFR [27]. Another cause are the mutations 
of KRAS, NRAS, BRAF and PIK3K genes located in the lower part 
of the EGFR signalling pathway, not controlled by EGFR. PIK3K 
mutations may occur simultaneously with the mutations in 
KRAS or BRAF genes, whilst KRAS and BRAF mutations occur 
independently. Moreover, mutations in 12, 13, 61, 146 codons 
of the KRAS gene and mutations V600E of the BRAF gene initi-
ate an independent route of pathway activation, a permanent 
activation of the MEK protein kinase, and, as a consequence, 
the failure of the anti-EGFR therapy. The proliferation pathway 
of the colorectal cancer is presented on Figure 4.
Immunohistochemical evaluation of the EGFR protein 
expression was not regarded as a predictive factor and 
no patient should be excluded from the treatment with 
anti-EGFR antibodies on the basis of immunohistochemi-
cal lack of EGFR protein expression [29, 30]. This results, 
among others, from the fact that the outcome of the reac-
tion might be uncertain as it depends, to a large degree, 
from the method of preserving the tissue and the period of 
the storage of the material [31]. In accordance with the NCCN 
(National Comprehensive Cancer Network) guidelines, it is 
recommended to identify KRAS and NRAS mutations in all 
patients with advanced colorectal cancer (stage IV) [32]. In 
July 2013 the European Medicines Agency (EMEA) updated 
the qualification criteria for anti-EGFR therapy, recommend-
ing obligatory identification of KRAS and NRAS mutations in 
exons 2, 3 and 4 [33, 34].
The analysis of the mutations in KRAS, NRAS, BRAF and 
PIK3K genes has a predictive value. It identifies the patients 
who will not benefit from the anti-EGFR therapy. The mu-
tation of the KRAS gene, present in 35% to 45% cases of 
colorectal cancer has the highest clinical value. It is a sig-
nificant predictive factor of the resistance to the treatment 
with cetuximab and panitumumab. The mutations of the 
BRAF, PIK3CA genes and the loss of PTEN expression are also 
included into the predictive factors of colorectal cancer [35]. 
They predict the lack of response to the treatment with 
anti-EGFR antibodies. Their application in practice, however, 
requires some further clinical research. 
Figure 3a. Colorectal tubular adenoma with high degree endothelial 
dysplasia/neoplasia, H&E staining, magnitude: 100×
Figure 3b. Colorectal tubular adenoma with high degree endothelial 
dysplasia/neoplasia, IHC — protein accumulation TP53, magnitude: 40×
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BRAF gene mutation (IIA)
The BRAF gene mutation (IIA) occurs in less than 15% 
cases of the colorectal cancer and in 90% cases it concerns 
V600E codon. BRAF is serine/threonine kinase activating 
MAP/ERK kinases from the RAF family leading to the activa-
tion of MEK and, EGFR-independent proliferation of cancer 
cells (Fig. 4) [36]. The mutations of the BRAF gene correlate 
with the MSI molecular subtype and the phenotype of the 
mutated CpG islands. The correlation between MSI, CIMP 
and BRAF is illustrated on Figure 5. 
Cancers with the BRAF gene mutation have different phe-
notypes from the wild types, without any mutations. In such 
cases, the patients are mostly women above 70 years of age 
with tumours located in the proximal part of the colon. Here 
mucinous and poorly differentiated cancers are dominating 
with metastases mostly to the lymph nodes and more rarely 
to the lungs [36, 37]. The BRAF mutation indicates an adverse 
course of the disease [38], yet its prediction significance still 
remains an issue that requires some further research [34]. The 
BRAF gene, a modulator of the MAPK pathway, may become 
a promising target of personalised therapy as a resistance 
biomarker. The research shows that it is responsible for about 
12–15% of failures of the anti-EGFR therapy [36, 39]. Accord-
ing to the studies of Richman et al., identifying the BRAF 
gene mutation may be a valuable predictive factor for a poor 
response to cetuximab, however, it is not a predictive factor 
for the therapy with the use of irinotecan or oxaliplatin [40].
PIK3K gene mutations (IIA) 
PIK3K gene mutations occur in 20% or less than 20% of 
cases of colorectal cancer. They are connected with an adverse 
course of the disease and the lack of response to treatment with 
anti-EGFR antibodies. The predictive value of this gene is more 
useful in connection with the evaluation of the expression of 
PTEN, a negative regulator of apoptosis inhibition pathway 
and cell proliferation [34]. In accordance with the current state 
of knowledge, mutations in exons 9 and 20 PIK3K may be the 
cause of cetuximab and panitumumab resistance.
Wnt pathway (IIB)
The most frequently occurring somatic mutation in 
colorectal cancer is the mutation of the APC gene (80% 
of cases), which activates the Wnt signalling pathway. The 
loss of function of the APC protein impairs b-catenin phos-
phorylation, and this substance, accumulated in the cell 
nucleus, potentiates the expression of the genes stimulat-
ing the proliferation processes [41]. Currently there are 
attempts made at inhibiting this pathway with the use of 
Figure 4. Colorectal cancer proliferation pathway (the authors own work on the basis of M. Berg’s publication [28])
Figure 5. Relationship between CIMP, MSI and BRAF
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the available therapeutic agents, yet no efficient inhibi-
tors have been found. As for the time being, the status of 
a predictive marker for the Wnt pathway may belong to 
immunohistochemistry evaluation of the nuclear b-catenin 
expression, which points to increased proliferation [42].
MMR gene disorders (IIC)
About 15% of cases of colorectal cancers display the 
disorders of the MMR mutator genes. The majority of them 
are cases of sporadic cancer, in which there are somatic 
mutations and epigenetic disorders, most frequently the 
hypermethylations of the MLH1 gene promotor. Inactivation 
of the MSH2 and MSH6 genes occurs much less frequent- 
ly [43]. In these cases the evaluation of the methylation of 
the MLH1 gene promotor has a predictive value. It allows the 
selection of a group of patients with a cancer of the MSI-H 
type with a similar microscopic image to Lynch syndrome, 
yet with a different phenotype. It must be stressed that 70% 
of cases of colorectal cancers with MLH1 hypermethylation 
display the BRAF gene mutation, which is a predictive factor 
in anti-EGFR therapy (cetuximab and panitumumab).
The IHC test of MLH1hypermethylation and the analysis 
of BRAF V600E mutations are predictive factors in sporadic 
cancers with MSI-H. An immunohistochemistry test is a bet-
ter and less expensive method than the molecular examina-
tion of the mutations of the MMR mutator genes. Apart from 
the above biomarkers which are useful in targeted therapies, 
the evaluations of topoisomerase inhibitors, PARP1 inhibi-
tors and PI3K-AKT-mTOR pathway inhibitors are also useful.
Moreover, patients with sporadic colorectal cancers 
with MSI-H do not benefit from the classical adjuvant thera-
py which is based on 5-Fluorouracil, yet the cancer cell lines 
may be more sensitive to treatment with irinotecan [44].
The summary of diagnostic, prognostic and predictive 
biomarkers as well as carcinogenesis paths with a useful set 
of immunohistochemicalis and molecular tests is presented 
below (Fig. 6).
miRNA as a prognostic and predictive marker 
A prognostic and predictive marker as well as a potential 
target of the therapy is microRNA (miRNA). This is a class of 
small, endogenous, single-stranded RNA, which play a role 
as post-transcriptive regulators taking part in carcinogen-
esis, invasion and progression of colorectal cancer [45, 46]. 
The work published in 2014 by Stiegelbauer et al. presents 
the characteristics of the miRNA studied so far together 
with their predictive value in the therapy of the patients 
with colorectal cancer.
Morphological and molecular classifications 
During recent years there have been attempts to create 
morphological and molecular classifications which could di-
vide patients into groups correlating with responses to treat-
ment. None of the many publications concerning colorectal 
cancer, such as Jass’s classification from 2007 [47], Furlan’s 
from 2011 or Sadanandam’s [48] or Roepman’s from 2014, 
found application and general approval in clinical practice. 
It was shown, however, that the classifications based on 
cellular phenotype and the molecular disorders connected 
with carcinogenesis have a larger value than classifications 
based solely on the molecular phenotype (e.g. those based 
on micro-RNA analysis).
Figure 6. A list of biomarkers useful in the diagnostics of colorectal cancer
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Summary
Analysis of biomarkers in colorectal cancer requires, 
from a pathologist, the application of immunohistochem-
istry methods and molecular studies for the diagnostics. 
The first group of biomarkers has diagnostic and prognostic 
significance. It should be routinely available in pathology 
departments dealing with histopathological oncological 
diagnostics. The latter group comprises the biomarkers with 
predictive significance in respect to molecularly targeted 
therapy. They are analysed with both immunochemistry and 
molecular methods, which should be based on validated 
techniques, subject to quality control. 
The clinical significance of the evaluation of predic-
tive factors consists of the correct qualification of patients 
for the therapy oriented at the regulation of the disorders 
leading to carcinogenesis and whose aim is the selective 
destruction of cancer cells. On the basis of the analysis of 
biomarker expression, the patients who will not benefit 
from such treatment are identified. There are two strategies 
for selecting patients for the therapy which is molecularly 
oriented. The first one is connected with identification of 
the factor connected with the drug effect, whilst the other 
strategy consists of the identification of the patients who 
will benefit from the treatment. The determination of the 
predictive factors allows therefore to exclude the patients 
who will not benefit from personalised therapy. In the area 
of clinical trials, new predictive factors come up and they 
are able to predict the efficacy of a drug in a connection 
with its target. 
The analysis of prognostic and diagnostic factors en-
larges the standard scope of pathological diagnostics by 
taking histogenesis and molecular disorders which are the 
core of cancer development into account. In the era of tar-
geted therapy, the pathological diagnostics concerns three 
directions, as recommended by ASCO/CAP 2015: 1. The 
evaluation of microsatellite instability as a prognostic and 
predictive factor in patients with MSI-H in Lynch syndrome 
and in sporadic cancer; 2. The evaluation of predictive fac-
tors in cancers with MSI-H on the basis of IHC analysis of 
MLH1 hypermethylation and the analysis of the BRAF V600E 
mutation; 3. The molecular analysis of the status of the KRAS 
and NRAS genes as a predictive factor of the lack of response 
to the anti-EGFR therapy.
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